Hengrui Pharmaceutical announced that its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. has received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for injectable HRS5580, which will conduct clinical trials in the near future.
恒瑞医药：子公司注射用HRS5580获得药物临床试验批准通知书
Hengrui Pharmaceutical: The subsidiary HRS5580 for injection obtained a notice of approval for clinical trials of the drug
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.